Nathaniel Mabe, Ph.D., Pharm.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Mammary Neoplasms, Animal | 2 | 2020 | 123 | 0.840 |
Why?
|
Gangliosides | 1 | 2022 | 132 | 0.790 |
Why?
|
Neuroblastoma | 3 | 2024 | 1240 | 0.710 |
Why?
|
Neoplasm Recurrence, Local | 6 | 2022 | 9207 | 0.580 |
Why?
|
Histone-Lysine N-Methyltransferase | 1 | 2020 | 680 | 0.540 |
Why?
|
Apoptosis Regulatory Proteins | 2 | 2018 | 1135 | 0.530 |
Why?
|
Gene Expression Regulation, Neoplastic | 8 | 2024 | 8420 | 0.520 |
Why?
|
Gene Silencing | 2 | 2020 | 1514 | 0.510 |
Why?
|
Epithelial-Mesenchymal Transition | 2 | 2020 | 726 | 0.480 |
Why?
|
Epigenesis, Genetic | 3 | 2024 | 3705 | 0.460 |
Why?
|
Receptor-Interacting Protein Serine-Threonine Kinases | 2 | 2020 | 139 | 0.330 |
Why?
|
Tumor Suppressor Proteins | 1 | 2018 | 2796 | 0.310 |
Why?
|
Mice, Nude | 3 | 2020 | 3582 | 0.240 |
Why?
|
RGS Proteins | 2 | 2016 | 75 | 0.230 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2018 | 5164 | 0.220 |
Why?
|
Vaccinia | 1 | 2022 | 71 | 0.210 |
Why?
|
Inflammation | 2 | 2020 | 10692 | 0.190 |
Why?
|
Cystine | 1 | 2020 | 94 | 0.170 |
Why?
|
Up-Regulation | 2 | 2020 | 4115 | 0.170 |
Why?
|
Histone Deacetylase Inhibitors | 1 | 2024 | 774 | 0.160 |
Why?
|
Histone Deacetylase 2 | 1 | 2018 | 72 | 0.160 |
Why?
|
Histone Deacetylase 1 | 1 | 2018 | 132 | 0.150 |
Why?
|
G-Protein-Coupled Receptor Kinase 2 | 1 | 2016 | 9 | 0.140 |
Why?
|
Breast Neoplasms | 3 | 2020 | 20844 | 0.140 |
Why?
|
Mitochondria, Heart | 1 | 2016 | 232 | 0.130 |
Why?
|
Neoplasms | 1 | 2024 | 21810 | 0.130 |
Why?
|
Cell Death | 1 | 2020 | 1663 | 0.120 |
Why?
|
Caspase 3 | 1 | 2016 | 730 | 0.120 |
Why?
|
Cell Line, Tumor | 5 | 2024 | 16739 | 0.110 |
Why?
|
Cell Survival | 2 | 2020 | 5775 | 0.110 |
Why?
|
Tumor Suppressor Protein p53 | 2 | 2020 | 2895 | 0.110 |
Why?
|
Molecular Targeted Therapy | 1 | 2024 | 2783 | 0.110 |
Why?
|
GTP-Binding Protein alpha Subunit, Gi2 | 1 | 2011 | 32 | 0.100 |
Why?
|
Forkhead Transcription Factors | 1 | 2018 | 1591 | 0.090 |
Why?
|
Animals | 9 | 2024 | 166825 | 0.090 |
Why?
|
DNA Methylation | 1 | 2024 | 4298 | 0.090 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2020 | 4343 | 0.080 |
Why?
|
Antineoplastic Agents | 2 | 2024 | 13558 | 0.080 |
Why?
|
Glioma | 1 | 2022 | 3394 | 0.070 |
Why?
|
Myocardial Reperfusion Injury | 1 | 2011 | 476 | 0.070 |
Why?
|
Transcription, Genetic | 1 | 2020 | 7570 | 0.070 |
Why?
|
Immunotherapy | 1 | 2022 | 4601 | 0.070 |
Why?
|
Myocardial Ischemia | 1 | 2016 | 2151 | 0.070 |
Why?
|
Antibodies, Monoclonal | 1 | 2022 | 9107 | 0.060 |
Why?
|
Nuclear Proteins | 1 | 2018 | 5786 | 0.060 |
Why?
|
Myocardial Infarction | 2 | 2016 | 11829 | 0.050 |
Why?
|
Myocardium | 2 | 2016 | 4650 | 0.050 |
Why?
|
Proto-Oncogene Protein c-fli-1 | 1 | 2023 | 103 | 0.050 |
Why?
|
Histone Acetyltransferases | 1 | 2024 | 332 | 0.050 |
Why?
|
Proto-Oncogene Proteins c-ets | 1 | 2023 | 311 | 0.050 |
Why?
|
Stress Disorders, Post-Traumatic | 1 | 2019 | 4470 | 0.050 |
Why?
|
RNA-Binding Protein EWS | 1 | 2023 | 209 | 0.050 |
Why?
|
Acetylation | 1 | 2024 | 1047 | 0.050 |
Why?
|
Vaccinia virus | 1 | 2022 | 331 | 0.050 |
Why?
|
Tumor Stem Cell Assay | 1 | 2020 | 115 | 0.040 |
Why?
|
Child | 3 | 2023 | 78996 | 0.040 |
Why?
|
Gene Amplification | 1 | 2024 | 1077 | 0.040 |
Why?
|
Mice | 4 | 2024 | 80551 | 0.040 |
Why?
|
Nervous System | 1 | 2022 | 540 | 0.040 |
Why?
|
Doxycycline | 1 | 2020 | 328 | 0.040 |
Why?
|
Humans | 9 | 2024 | 752810 | 0.040 |
Why?
|
Cats | 1 | 2019 | 969 | 0.040 |
Why?
|
Proto-Oncogene Proteins c-met | 1 | 2020 | 558 | 0.030 |
Why?
|
Female | 7 | 2020 | 386339 | 0.030 |
Why?
|
Protective Agents | 1 | 2016 | 151 | 0.030 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2023 | 1572 | 0.030 |
Why?
|
Mitosis | 1 | 2020 | 1191 | 0.030 |
Why?
|
Histones | 1 | 2024 | 2566 | 0.030 |
Why?
|
Signal Transduction | 4 | 2020 | 23235 | 0.030 |
Why?
|
Risk Factors | 1 | 2020 | 73418 | 0.030 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2023 | 2821 | 0.030 |
Why?
|
Chromatin | 1 | 2024 | 2916 | 0.030 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2020 | 3552 | 0.030 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2022 | 2863 | 0.030 |
Why?
|
Fibrosis | 1 | 2019 | 2011 | 0.030 |
Why?
|
Drug Design | 1 | 2016 | 1057 | 0.020 |
Why?
|
KATP Channels | 1 | 2011 | 45 | 0.020 |
Why?
|
Potassium Channel Blockers | 1 | 2011 | 162 | 0.020 |
Why?
|
Receptor, erbB-2 | 1 | 2020 | 2483 | 0.020 |
Why?
|
Least-Squares Analysis | 1 | 2011 | 366 | 0.020 |
Why?
|
Single-Cell Analysis | 1 | 2020 | 2318 | 0.020 |
Why?
|
Piperazines | 1 | 2020 | 2487 | 0.020 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2020 | 2900 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2018 | 2440 | 0.020 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2018 | 2868 | 0.020 |
Why?
|
Potassium Channels | 1 | 2011 | 537 | 0.020 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2020 | 3600 | 0.020 |
Why?
|
Cardiotonic Agents | 1 | 2011 | 547 | 0.020 |
Why?
|
Mice, Mutant Strains | 1 | 2011 | 1765 | 0.020 |
Why?
|
Disease Models, Animal | 2 | 2019 | 17960 | 0.020 |
Why?
|
Endothelial Cells | 1 | 2019 | 3513 | 0.020 |
Why?
|
Promoter Regions, Genetic | 1 | 2018 | 5780 | 0.020 |
Why?
|
Perfusion | 1 | 2011 | 1363 | 0.020 |
Why?
|
Myocardial Contraction | 1 | 2011 | 1510 | 0.020 |
Why?
|
Cell Proliferation | 1 | 2020 | 10358 | 0.010 |
Why?
|
Stress, Psychological | 1 | 2019 | 4338 | 0.010 |
Why?
|
Rats | 1 | 2019 | 23565 | 0.010 |
Why?
|
Wounds and Injuries | 1 | 1995 | 2426 | 0.010 |
Why?
|
Alcohol Drinking | 1 | 1995 | 3991 | 0.010 |
Why?
|
Analysis of Variance | 1 | 2011 | 6245 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2016 | 14296 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2011 | 10798 | 0.010 |
Why?
|
Genotype | 1 | 2011 | 12869 | 0.010 |
Why?
|
Lung Neoplasms | 1 | 2020 | 13173 | 0.010 |
Why?
|
Phenotype | 1 | 2011 | 16440 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2011 | 21724 | 0.010 |
Why?
|
Male | 3 | 2019 | 355160 | 0.010 |
Why?
|
Cross-Over Studies | 1 | 1995 | 2037 | 0.010 |
Why?
|
Mutation | 1 | 2011 | 29712 | 0.000 |
Why?
|
Odds Ratio | 1 | 1995 | 9701 | 0.000 |
Why?
|
Research Design | 1 | 1995 | 6118 | 0.000 |
Why?
|
Case-Control Studies | 1 | 1995 | 21857 | 0.000 |
Why?
|
Time Factors | 1 | 1995 | 39885 | 0.000 |
Why?
|
Aged, 80 and over | 1 | 1995 | 58347 | 0.000 |
Why?
|
Aged | 1 | 1995 | 166705 | 0.000 |
Why?
|
Middle Aged | 1 | 1995 | 217250 | 0.000 |
Why?
|
Adult | 1 | 1995 | 217168 | 0.000 |
Why?
|